16 . December , 2017 - Saturday
Check todays hot topics or new products

Find a Drug: Advanced

Please Sign in or Register

All about: Midazolam Syrup

Big Image
Generic Name: Midazolam hydrochloride
Dosage Form: Syrup

Midazolam HCl syrup has been associated with respiratory depression and respiratory arrest, especially when used for sedation in noncritical care settings. Midazolam HCl syrup has been associated with reports of respiratory depression, airway obstruction, desaturation, hypoxia, and apnea, most often when used concomitantly with other central nervous system depressants (eg, opioids). Midazolam HCl syrup should be used only in hospital or ambulatory care settings, including physicians' and dentists' offices, THAT CAN PROVIDE FOR CONTINUOUS MONITORING OF RESPIRATORY AND CARDIAC FUNCTION. IMMEDIATE AVAILABILITY OF RESUSCITATIVE DRUGS AND AGE- AND SIZE- APPROPRIATE EQUIPMENT FOR VENTILATION AND INTUBATION, AND PERSONNEL TRAINED IN THEIR USE AND SKILLED IN AIRWAY MANAGEMENT SHOULD BE ASSURED (see WARNINGS). For deeply sedated patients, a dedicated individual, other than the practitioner performing the procedure, should monitor the patient throughout the procedure.

DESCRIPTION:

Midazolam is a benzodiazepine available as Midazolam HCl syrup for oral administration. Midazolam, a white to light yellow crystalline compound, is insoluble in water, but can be solubilized in aqueous solutions by formation of the hydrochloride salt in situ under acidic conditions. Chemically, Midazolam HCl is 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4] benzodiazepine hydrochloride. Midazolam hydrochloride has the molecular formula C18H13ClFN3•HCl, a calculated molecular weight of 362.25 and the following structural formula:

Each mL of the syrup contains Midazolam hydrochloride equivalent to 2 mg Midazolam compounded with artificial bitterness modifier, citric acid anhydrous, D&C Red #33, edetate disodium, glycerin, mixed fruit flavor, sodium benzoate, sodium citrate, sorbitol, and water; the pH is adjusted to 2.8 - 3.6 with hydrochloric acid.

Under the acidic conditions required to solubilize Midazolam in the syrup, Midazolam is present as an equilibrium mixture (shown below) of the closed ring form shown above and an open-ring structure formed by the acid-catalyzed ring opening of the 4,5-double bond of the diazepine ring. The amount of open-ring form is dependent upon the pH of the solution. At the specified pH of the syrup, the solution may contain up to about 40% of the open-ring compound. At the physiologic conditions under which the product is absorbed (pH of 5 to 8) into the systemic circulation, any open-ring form present reverts to the physiologically active, lipophilic, closed-ring form (Midazolam) and is absorbed as such.

The following chart plots the percentage of Midazolam present as the open-ring form as a function of pH in aqueous solutions. As indicated in the graph, the amount of open-ring compound present in solution is sensitive to changes in pH over the pH range specified for the product: 2.8 to 3.6. Above pH 5, at least 99% of the mixture is present in the closed-ring form.

CLINICAL PHARMACOLOGY:

Midazolam is a short-acting benzodiazepine central nervous system (CNS) depressant.

Pharmacodynamics:

Pharmacodynamic properties of Midazolam and its metabolites, which are similar to those of other benzodiazepines, include sedative, anxiolytic, amnesic and hypnotic activities. Benzodiazepine pharmacologic effects appear to result from reversible interactions with the γ-amino butyric acid (GABA) benzodiazepine receptor in the CNS, the major inhibitory neurotransmitter in the central nervous system. The action of Midazolam is readily reversed by the benzodiazepine receptor antagonist, flumazenil.

Data from published reports of studies in pediatric patients clearly demonstrate that oral Midazolam provides safe and effective sedation and anxiolysis prior to surgical procedures that require anesthesia as well as before other procedures that require sedation but may not require anesthesia. The most commonly reported effective doses range from 0.25 to 1 mg/kg in children (6 months to <16 years). The single most commonly reported effective dose is 0.5 mg/kg. Time to onset of effect is most frequently reported as 10 to 20 minutes.

The effects of Midazolam on the CNS are dependent on the dose administered, the route of administration, and the presence or absence of other medications.

Following premedication with oral Midazolam, time to recovery has been assessed in pediatric patients using various measures, such as time to eye opening, time to extubation, time in the recovery room, and time to discharge from the hospital. Most placebo-controlled trials (8 total) have shown little effect of oral Midazolam on recovery time from general anesthesia; however, a number of other placebo-controlled studies (5 total) have demonstrated some prolongation in recovery time following premedication with oral Midazolam. Prolonged recovery may be related to duration of the surgical procedure and/or use of other medications with central nervous system depressant properties.

Partial or complete impairment of recall following oral Midazolam has been demonstrated in several studies. Amnesia for the surgical experience was greater after oral Midazolam when used as a premedicant than after placebo and was generally considered a benefit. In one study, 69% of Midazolam patients did not remember mask application versus 6% of placebo patients.

Episodes of oxygen desaturation, respiratory depression, apnea, and airway obstruction have been reported in <1% of pediatric patients following premedication (eg, sedation prior to induction of anesthesia) with Midazolam HCl syrup; the potential for such adverse events are markedly increased when oral Midazolam is combined with other central nervous system depressing agents and in patients with abnormal airway anatomy, patients with cyanotic congenital heart disease, or patients with sepsis or severe pulmonary disease (see WARNINGS).

Concomitant use of barbiturates or other central nervous system depressants may increase the risk of hypoventilation, airway obstruction, desaturation or apnea, and may contribute to profound and/or prolonged drug effect. In one study of pediatric patients undergoing elective repair of congenital cardiac defects, premedication regimens (oral dose of 0.75 mg/kg Midazolam or IM morphine plus scopolamine) increased transcutaneous carbon dioxide (PtcCO2), decreased SpO2 (as measured by pulse oximetry), and decreased respiratory rates preferentially in patients with pulmonary hypertension. This suggests that hypercarbia or hypoxia following premedication might pose a risk to children with congenital heart disease and pulmonary hypertension. In a study of an adult population 65 years and older, the preinduction administration of oral Midazolam 7.5 mg resulted in a 60% incidence of hypoxemia (paO2<90% for over 30 seconds) at some time during the operative procedure versus 15% for the nonpremedicated group.

Pharmacokinetics:

Absorption:

Midazolam is rapidly absorbed after oral administration and is subject to substantial intestinal and hepatic first-pass metabolism. The pharmacokinetics of Midazolam and its major metabolite, α-hydroxyMidazolam, and the absolute bioavailability of Midazolam HCl syrup were studied in pediatric patients of different ages (6 months to <16 years old) over a 0.25 to 1 mg/kg dose range. Pharmacokinetic parameters from this study are presented in Table 1. The mean Tmax values across dose groups (0.25, 0.5, and 1 mg/kg) range from 0.17 to 2.65 hours. Midazolam exhibits linear pharmacokinetics between oral doses of 0.25 to 1 mg/kg (up to a maximum dose of 40 mg) across the age groups ranging from 6 months to <16 years. Linearity was also demonstrated across the doses within the age group of 2 years to <12 years having 18 patients at each of the three doses. The absolute bioavailability of the Midazolam syrup in pediatric patients is about 36%, which is not affected by pediatric age or weight. The AUC0-∞ ratio of α-hydroxyMidazolam to Midazolam for the oral dose in pediatric patients is higher than for an IV dose (0.38 to 0.75 versus 0.21 to 0.39 across the age group of 6 months to <16 years), and the AUC0-∞ ratio of α-hydroxy-Midazolam to Midazolam for the oral dose is higher in pediatric patients than in adults (0.38 to 0.75 versus 0.40 to 0.56).

Food effect has not been tested using Midazolam HCl syrup. When a 15 mg oral tablet of Midazolam was administered with food to adults, the absorption and disposition of Midazolam was not affected. Feeding is generally contraindicated prior to sedation of pediatric patients for procedures.

Table1.Pharmacokinetics of Midazolam Following Single Dose Administration of Midazolam HCl Syrup
Number of Subjects/age group Dose
(mg/kg)
Tmax
(h)
Cmax
(ng/mL)
T1/2
(h)
AUC 0-∞
(ng∙h/mL)
6 months to <2 years old
1 0.25 0.17 28.0 5.82 67.6
1 0.50 0.35 66.0 2.22 152
1 1.00 0.17 61.2 2.97 224
2 to <12 years old
18 0.25 0.72 ± 0.44 63.0 ± 30.0 3.16 ± 1.50 138 ± 89.5
18 0.50 0.95 ± 0.53 126 ± 75.8 2.71 ± 1.09 306 ± 196
18 1.00 0.88 ± 0.99 201 ± 101 2.37 ± 0.96 743 ± 642
12 to <16 years old
4 0.25 2.09 ± 1.35 29.1 ± 8.2 6.83 ± 3.84 155 ± 84.6
4 0.50 2.65 ± 1.58 118 ± 81.2 4.35 ± 3.31 821 ± 568
2 1.00 0.55 ± 0.28 191 ± 47.4 2.51 ± 0.18 566 ± 15.7

Distribution:

The extent of plasma protein binding of Midazolam is moderately high and concentration independent. In adults and pediatric patients older than 1 year, Midazolam is approximately 97% bound to plasma protein, principally albumin. In healthy volunteers, α-hydroxyMidazolam is bound to the extent of 89%. In pediatric patients (6 months to <16 years) receiving 0.15 mg/kg IV Midazolam, the mean steady-state volume of distribution ranged from 1.24 to 2.02 L/kg.

Metabolism:

Midazolam is primarily metabolized in the liver and gut by human cytochrome P450 IIIA4 (CYP3A4) to its pharmacologic active metabolite, α-hydroxyMidazolam, followed by glucuronidation of the α–hydroxyl metabolite which is present in unconjugated and conjugated forms in human plasma. The α- hydroxyMidazolam glucuronide is then excreted in urine. In a study in which adult volunteers were administered intravenous Midazolam (0.1 mg/kg) and α–hydroxyMidazolam (0.15 mg/kg), the pharmacodynamic parameter values of the maximum effect (Emax) and concentration eliciting half-maximal effect (EC50) were similar for both compounds. The effects studied were reaction time and errors in tracing tests. The results indicate that α–hydroxyMidazolam is equipotent and equally effective as unchanged Midazolam on a total plasma concentration basis. After oral or intravenous administration, 63% to 80% of Midazolam is recovered in urine as α–hydroxyMidazolam glucuronide. No significant amount of parent drug or metabolites is extractable from urine before beta-glucuronidase and sulfatase deconjugation, indicating that the urinary metabolites are excreted mainly as conjugates.

Midazolam is also metabolized to two other minor metabolites: 4-hydroxy metabolite (about 3% of the dose) and 1,4-dihydroxy metabolite (about 1% of the dose) are excreted in small amounts in the urine as conjugates.

Elimination:

The mean elimination half-life of Midazolam ranged from 2.2 to 6.8 hours following single oral doses of 0.25, 0.5, and 1 mg/kg of Midazolam (Midazolam HCl syrup). Similar results (ranged from 2.9 to 4.5 hours) for the mean elimination half-life were observed following IV administration of 0.15 mg/kg of Midazolam to pediatric patients (6 months to <16 years old). In the same group of patients receiving the 0.15 mg/kg IV dose, the mean total clearance ranged from 9.3 to 11 mL/min/kg.

Pharmacokinetic-Pharmacodynamic Relationships:

The relationship between plasma concentration and sedation and anxiolysis scores of oral Midazolam syrup (single oral doses of 0.25, 0.5, or 1 mg/kg) was investigated in three age groups of pediatric patients (6 months to <2 years, 2 to <12 years, and 12 to <16 years old). In this study, the patient's sedation scores were recorded at baseline and at 10-minute intervals up to 30 minutes after oral dosing until satisfactory sedation ("drowsy" or "asleep but responsive to mild shaking" or "asleep and not responsive to mild shaking") was achieved. Anxiolysis scores were measured at the time when the patient was separated from his/her parents and at mask induction. The results of the analyses showed that the mean Midazolam plasma concentration as well as the mean of Midazolam plus α–hydroxyMidazolam for those patients with a sedation score of 4 (asleep but responsive to mild shaking) is significantly different than the mean concentrations for those patients with a sedation score of 3 (drowsy), which is significantly different than the mean concentrations for patients with a sedation score of 2 (awake/calm). The statistical analysis indicates that the greater the Midazolam, or Midazolam plus α–hydroxyMidazolam concentration, the greater the maximum sedation score for pediatric patients. No such trend was observed between anxiolysis scores and the mean Midazolam concentration or mean of Midazolam plus α–hydroxyMidazolam concentration; however, anxiolysis is a more variable surrogate measurement of clinical response.

Special Populations:

Renal Impairment:

Although the pharmacokinetics of intravenous Midazolam in adult patients with chronic renal failure differed from those of subjects with normal renal function, there were no alterations in the distribution, elimination, or clearance of unbound drug in the renal failure patients. However, the effects of renal impairment on the active metabolite α–hydroxyMidazolam are unknown.

Hepatic Dysfunction:

Chronic hepatic disease alters the pharmacokinetics of Midazolam. Following oral administration of 15 mg of Midazolam, Cmax and bioavailability values were 43% and 100% higher, respectively, in adult patients with hepatic cirrhosis than adult subjects with normal liver function. In the same patients with hepatic cirrhosis, following IV administration of 7.5 mg of Midazolam, the clearance of Midazolam was reduced by about 40% and the elimination half-life was increased by about 90% compared with subjects with normal liver function. Midazolam should be titrated for the desired effect in patients with chronic hepatic disease.

Congestive Heart Failure:

Following oral administration of 7.5 mg of Midazolam, elimination half-life values were 43% higher in adult patients with congestive heart failure than in control subjects.

Neonates:

Midazolam HCl syrup has not been studied in pediatric patients less than 6 months of age.

Drug-Drug Interactions:

See PRECAUTIONS: Drug Interactions.

INHIBITORS OF CYP3A4 ISOZYMES:

Table 2 summarizes the changes in the Cmax and AUC of Midazolam when drugs known to inhibit CYP3A4 were concurrently administered with oral Midazolam in adults subjects.

Table 2.
Interacting Drug Adult Doses Studied % Increase in Cmax of Oral Midazolam % Increase in AUC of Oral Midazolam
Cimetidine 800-1200 mg up to qid in divided doses 6-138 10-102
Diltiazem 60 mg tid 105 275
Erythromycin 500 mg tid 170-171 281-341
Fluconazole 200 mg qd 150 250
Grapefruit Juice 200 mL 56 52
Itraconazole 100-200 mg qd 80-240 240-980
Ketoconazole 400 mg qd 309 1490
Ranitidine 150 mg bid or tid; 300 mg qd 15-67 9-66
Roxithromycin 300 mg qd 37 47
Saquinavir 1200 mg tid 235 514
Verapamil 80 mg tid 97 192

Other drugs known to inhibit the effects of CYP3A4, such as protease inhibitors, would be expected to have similar effects on these Midazolam pharmacokinetic parameters.

INDUCERS OF CYP3A4 ISOZYMES:

Table 3 summarizes the changes in the Cmax and AUC of Midazolam when drugs known to induce CYP3A4 were concurrently administered with oral Midazolam in adult subjects. The clinical significance of these changes is unclear.

Table 3.
Interacting Drug Adult Doses Studied % Decrease in Cmax of Oral Midazolam % Decrease in AUC of Oral Midazolam
Carbamazepine Therapeutic Doses 93 94
Phenytoin Therapeutic Doses 93 94
Rifampin 600 mg/day 94 96

Although not tested, phenobarbital, rifabutin and other drugs known to induce the effects of CYP3A4 would be expected to have similar effects on these Midazolam pharmacokinetic parameters.

Drugs that did not affect Midazolam pharmacokinetics are presented in Table 4.

Table 4.
Interacting Drug Adult Doses Studied
Azithromycin 500 mg/day
Nitrendipine 20 mg
Terbinafine 200 mg/day

Clinical Trials:

Dose Ranging, Safety and Efficacy Study With Midazolam HCl Syrup in Pediatric Patients:

The effectiveness of Midazolam HCl syrup as a premedicant to sedate and calm pediatric patients prior to induction of general anesthesia was compared among three different doses in a randomized, double-blind, parallel-group study. Patients of ASA physical status I, II or III were stratified to 1 of 3 age groups (6 months to <2 years, 2 to <6 years, and 6 to <16 years), and within each age group randomized to 1 of 3 dosing groups (0.25, 0.5, and 1 mg/kg up to a maximum dose of 20 mg). Greater than 90% of treated patients achieved satisfactory sedation and anxiolysis at at least one timepoint within 30 minutes posttreatment. Similarly high proportions of patients exhibited satisfactory ease of separation from parent or guardian and were cooperative at the time of mask induction with nitrous oxide and halothane administration. Onset time of satisfactory sedation or anxiolysis occurred within 10 minutes after treatment for >70% of patients who started with an unsatisfactory baseline rating. Whereas pairwise comparisons (0.25 mg/kg versus 0.5 mg/kg groups, and 0.5 mg/kg versus 1 mg/kg groups) on satisfactory sedation did not yield significant p-values (p=0.08 in both cases), comparative analysis of the clinical response between the high and low doses demonstrated that a higher proportion of patients in the 1 mg/kg dose group exhibited satisfactory sedation and anxiolysis as compared to the 0.25 mg/kg group (p<0.05).

INDICATIONS AND USAGE:

Midazolam HCl syrup is indicated for use in pediatric patients for sedation, anxiolysis and amnesia prior to diagnostic, therapeutic or endoscopic procedures or before induction of anesthesia.

Midazolam HCl syrup is intended for use in monitored settings only and not for chronic or home use (see WARNINGS).

Midazolam HCl SYRUP MUST BE USED AS SPECIFIED IN THE LABEL.

Midazolam is associated with a high incidence of partial or complete impairment of recall for the next several hours (see CLINICAL PHARMACOLOGY).

CONTRAINDICATIONS:

Midazolam HCl syrup is contraindicated in patients with a known hypersensitivity to the drug or allergies to formulation excipients. Benzodiazepines are contraindicated in patients with acute narrow-angle glaucoma. Benzodiazepines may be used in patients with open-angle glaucoma only if they are receiving appropriate therapy. Measurements of intraocular pressure in patients without eye disease show a moderate lowering following induction of general anesthesia with injectable Midazolam; patients with glaucoma have not been studied.

WARNINGS:

Serious respiratory adverse events have occurred after administration of oral Midazolam, most often when Midazolam was used in combination with other central nervous system depressants. These adverse events have included respiratory depression, airway obstruction, oxygen desaturation, apnea, and rarely, respiratory and/or cardiac arrest (see box WARNING). When oral Midazolam is administered as the sole agent at recommended doses respiratory depression, airway obstruction, oxygen desaturation, and apnea occur infrequently (see DOSAGE AND ADMINISTRATION).

Prior to the administration of Midazolam in any dose, the immediate availability of oxygen, resuscitative drugs, age- and size-appropriate equipment for bag/valve/mask ventilation and intubation, and skilled personnel for the maintenance of a patent airway and support of ventilation should be ensured. Midazolam HCl syrup must never be used without individualization of dosage, particularly when used with other medications capable of producing central nervous system depression.

Midazolam HCl syrup should be used only in hospital or ambulatory care settings, including physicians' and dentists' offices, that are equipped to provide continuous monitoring of respiratory and cardiac function. Midazolam HCl syrup must only be administered to patients if they will be monitored by direct visual observation by a health care professional. If Midazolam HCl syrup will be administered in combination with other anesthetic drugs or drugs which depress the central nervous system, patients must be monitored by persons specifically trained in the use of these drugs and, in particular, in the management of respiratory effects of these drugs, including respiratory and cardiac resuscitation of patients in the age group being treated.

For deeply sedated patients, a dedicated individual whose sole responsibility is to observe the patient, other than the practitioner performing the procedure, should monitor the patient throughout the procedure.

Patients should be continuously monitored for early signs of hypoventilation, airway obstruction, or apnea with means for detection readily available (eg, pulse oximetry). Hypoventilation, airway obstruction, and apnea can lead to hypoxia and/or cardiac arrest unless effective countermeasures are taken immediately. The immediate availability of specific reversal agents (flumazenil) is highly recommended. Vital signs should continue to be monitored during the recovery period. Because Midazolam can depress respiration (see CLINICAL PHARMACOLOGY), especially when used concomitantly with opioid agonists and other sedatives (see DOSAGE AND ADMINISTRATION), it should be used for sedation/anxiolysis/amnesia only in the presence of personnel skilled in early detection of hypoventilation, maintaining a patent airway, and supporting ventilation.

Episodes of oxygen desaturation, respiratory depression, apnea, and airway obstruction have been occasionally reported following premedication (sedation prior to induction of anesthesia) with oral Midazolam; such events are markedly increased when oral Midazolam is combined with other central nervous system depressing agents and in patients with abnormal airway anatomy, patients with cyanotic congenital heart disease, or patients with sepsis or severe pulmonary disease.

Reactions such as agitation, involuntary movements (including tonic/clonic movements and muscle tremor), hyperactivity and combativeness have been reported in both adult and pediatric patients. Consideration should be given to the possibility of paradoxical reaction. Should such reactions occur, the response to each dose of Midazolam and all other drugs, including local anesthetics, should be evaluated before proceeding. Reversal of such responses with flumazenil has been reported in pediatric and adult patients.

Concomitant use of barbiturates, alcohol or other central nervous system depressants may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect. Narcotic premedication also depresses the ventilatory response to carbon dioxide stimulation.

Coadministration of oral Midazolam in patients who are taking ketoconazole, intraconazole and saquinavir has been shown to result in large increases in Cmax and AUC of Midazolam due to decrease in plasma clearance of Midazolam (see PHARMACOKINETICS: Drug-Drug Interactions and PRECAUTIONS). Due to potential for intense and prolonged sedation and respiratory depression, Midazolam syrup should only be coadministered with these medications if absolutely necessary and with appropriate equipment and personnel available to respond to respiratory insufficiency.

Higher risk pediatric surgical patients may require lower doses, whether or not concomitant sedating medications have been administered. Pediatric patients with cardiac or respiratory compromise may be unusually sensitive to the respiratory depressant effect of Midazolam. Pediatric patients undergoing procedures involving the upper airway such as upper endoscopy or dental care, are particularly vulnerable to episodes of desaturation and hypoventilation due to partial airway obstruction. Patients with chronic renal failure and patients with congestive heart failure eliminate Midazolam more slowly (see CLINICAL PHARMACOLOGY).

The decision as to when patients who have received Midazolam HCl syrup, particularly on an outpatient basis, may again engage in activities requiring complete mental alertness, operate hazardous machinery or drive a motor vehicle must be individualized. Gross tests of recovery from the effects of Midazolam HCl syrup (see CLINICAL PHARMACOLOGY) cannot be relied upon to predict reaction time under stress. It is recommended that no patient operate hazardous machinery or a motor vehicle until the effects of the drug, such as drowsiness, have subsided or until one full day after anesthesia and surgery, whichever is longer. Particular care should be taken to assure safe ambulation.

Usage in Pregnancy:

Although Midazolam HCl syrup has not been studied in pregnant patients, an increased risk of congenital malformations associated with the use of benzodiazepine drugs (diazepam and chlordiazepoxide) have been suggested in several studies. If this drug is used during pregnancy, the patient should be apprised of the potential hazard to the fetus.

Usage in Preterm Infants and Neonates:

Midazolam HCl syrup has not been studied in patients less than 6 months of age.

PRECAUTIONS:

Use With Other CNS Depressants:

The efficacy and safety of Midazolam in clinical use are functions of the dose administered, the clinical status of the individual patient, and the use of concomitant medications capable of depressing the CNS. Anticipated effects may range from mild sedation to deep levels of sedation with a potential loss of protective reflexes, particularly when coadministered with anesthetic agents or other CNS depressants. Care must be taken to individualize the dose of Midazolam based on the patient's age, underlying medical/surgical conditions, concomitant medications, and to have the personnel, age- and size-appropriate equipment and facilities available for monitoring and intervention. Practitioners administering Midazolam must have the skills necessary to manage reasonably foreseeable adverse effects, particularly skills in airway management.

Use With Inhibitors of CYP3A4 Isozymes:

Oral Midazolam should be used with caution in patients treated with drugs known to inhibit CYP3A4 because inhibition of metabolism may lead to more intense and prolonged sedation (see PHARMACOKINETICS: Drug-Drug Interactions, and WARNINGS). Patients being treated with medications known to inhibit CYP3A4 isozymes should be treated with lower than recommended doses of Midazolam HCl syrup and the clinician should expect a more intense and prolonged effect.

Information for Patients:

To assure safe and effective use of Midazolam HCl syrup, the following information and instructions should be communicated to the patient when appropriate:

  1. Inform your physician about any alcohol consumption and medicine you are now taking, especially blood pressure medication, antibiotics, and protease inhibitors, including drugs you buy without a prescription. Alcohol has an increased effect when consumed with benzodiazepines; therefore, caution should be exercised regarding simultaneous ingestion of alcohol during benzodiazepine treatment.
  2. Inform your physician if you are pregnant or are planning to become pregnant.
  3. Inform your physician if you are nursing.
  4. Patients should be informed of the pharmacological effects of Midazolam HCl syrup, such as sedation and amnesia, which in some patients may be profound. The decision as to when patients who have received Midazolam HCl syrup, particularly on an outpatient basis, may again engage in activities requiring complete mental alertness, operate hazardous machinery or drive a motor vehicle must be individualized.
  5. Midazolam HCl syrup should not be taken in conjunction with grapefruit juice.
  6. For pediatric patients, particular care should be taken to assure safe ambulation.

Drug Interactions:

Inhibitors of CYP3A4 Isozymes:

Caution is advised when Midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). Drugs such as diltiazem, erythromycin, fluconazole, itraconazole, ketoconazole, saquinavir, and verapamil were shown to significantly increase the Cmax and AUC of orally administered Midazolam. These drug interactions may result in increased and prolonged sedation due to a decrease in plasma clearance of Midazolam. Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of Midazolam. Caution is advised when Midazolam HCl syrup is used concomitantly with these drugs. Dose adjustments should be considered and possible prolongation and intensity of effect should be anticipated (see PHARMACOKINETICS: Drug-Drug Interactions).

Inducers of CYP3A4 Isozymes:

Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased Cmax and AUC of oral Midazolam in adult studies. Although clinical studies have not been performed, phenobarbital is expected to have the same effect. Caution is advised when administering Midazolam HCl syrup to patients receiving these medications and if necessary dose adjustments should be considered.

CNS Depressants:

One case was reported of inadequate sedation with chloral hydrate and later with oral Midazolam due to a possible interaction with methylphenidate administered chronically in a 2-year-old boy with a history of Williams syndrome. The difficulty in achieving adequate sedation may have been the result of decreased absorption of the sedatives due to both the gastrointestinal effects and stimulant effects of methylphenidate.

The sedative effect of Midazolam HCl syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. Consequently, the dose of Midazolam HCl syrup should be adjusted according to the type and amount of concomitant medications administered and the desired clinical response (see DOSAGE AND ADMINISTRATION).

No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.

Drug/Laboratory Test Interactions:

Midazolam has not been shown to interfere with results obtained in clinical laboratory tests.

Carcinogenesis, Mutagenesis and Impairment of Fertility:

Carcinogenesis:

Midazolam maleate was administered with diet in mice and rats for 2 years at dosages of 1, 9, and 80 mg/kg/day. In female mice in the highest dose (10 times the highest oral dose of 1 mg/kg for a pediatric patient, on a mg/m2 basis) group there was a marked increase in the incidence of hepatic tumors. In high-dose (19 times the pediatric dose) male rats there was a small but statistically significant increase in benign thyroid follicular cell tumors. Dosages of 9 mg/kg/day of Midazolam maleate (1 to 2 times the pediatric dose) did not increase the incidence of tumors in mice or rats. The pathogenesis of induction of these tumors is not known. These tumors were found after chronic administration, whereas human use will ordinarily be single or intermittent doses.

Mutagenesis:

Midazolam did not have mutagenic activity in Salmonella typhimurium (5 bacterial strains), Chinese hamster lung cells (V79), human lymphocytes or in the micronucleus test in mice.

Impairment of Fertility:

A reproduction study in male and female rats did not show any impairment of fertility at dosages up to 16 mg/kg/day PO (3 times the human dose of 1 mg/kg, on a mg/m2 basis).

Pregnancy:

Teratogenic Effects:

Pregnancy Category D

(see WARNINGS).

Embryo-fetal development studies, performed with Midazolam maleate in mice (at up to 120 mg/kg/day PO, 10 times the human dose of 1 mg/kg on a mg/m2 basis), rats (at up to 4 mg/kg/day IV, 8 times the human IV dose of 5 mg) and rabbits (at up to 100 mg/kg/day PO, 32 times the human oral dose of 1 mg/kg on a mg/m2 basis), did not show evidence of teratogenicity.

Nonteratogenic Effects:

Studies in rats showed no adverse effects on reproductive parameters during gestation and lactation. Dosages tested (4 mg/kg IV and 50 mg/kg PO) were approximately 8 times each of the human doses on a mg/m2 basis.

Labor and Delivery:

In humans, measurable levels of Midazolam were found in maternal venous serum, umbilical venous and arterial serum and amniotic fluid, indicating placental transfer of the drug.

The use of Midazolam HCl syrup in obstetrics has not been evaluated in clinical studies. Because Midazolam is transferred transplacentally and because other benzodiazepines given in the last weeks of pregnancy have resulted in neonatal CNS depression, Midazolam syrup is not recommended for obstetrical use.

Nursing Mothers:

Midazolam is excreted in human milk. Caution should be exercised when Midazolam syrup is administered to a nursing woman.

Geriatric Use:

The safety and efficacy of this product have not been fully studied in geriatric patients. Therefore, there are no available data on a safe dosing regimen. One study in geriatric subjects, using Midazolam 7.5 mg as a premedicant prior to general anesthesia, noted a 60% incidence of hypoxemia (pO2<90% for over 30 seconds) at sometime during the operative procedure versus 15% for the nonpremedicated group. Until further information is available it is recommended that this product should not be used in geriatric patients.

Use in Patients With Heart Disease:

Following oral administration of 7.5 mg of Midazolam to adult patients with congestive heart failure, the half-life of Midazolam was 43% higher than in control subjects. One study suggests that hypercarbia or hypoxia following premedication with oral Midazolam might pose a risk to children with congenital heart disease and pulmonary hypertension, although there are no known reports of pulmonary hypertensive crises that had been triggered by premedication. In the study, 22 children were premedicated with oral Midazolam (0.75 mg/kg) or IM morphine plus scopolamine prior to elective repair of congenital cardiac defects. Both premedication regimens increased PtcCO2 and decreased SpO2 and respiratory rates preferentially in patients with pulmonary hypertension.

ADVERSE REACTIONS:

The distribution of adverse events occurring in patients evaluated in a randomized, double-blind, parallel-group trial are presented in Tables 5 and 6 by body system in order of decreasing frequency: for the premedication period (eg, sedation period prior to induction of anesthesia) alone, see Table 5; for over the entire monitoring period including premedication, anesthesia and recovery, see Table 6.

The distribution of adverse events occurring during the premedication period, before induction of anesthesia, is presented in Table 5. Emesis which occurred in 31/397 (8%) patients over the entire monitoring period, occurred in 3/397 (0.8%) of patients during the premedication period (from Midazolam administration to mask induction). Nausea, which occurred in 14/397 (4%) patients over the entire monitoring period (premedication, anesthesia and recovery), occurred in 2/397 (0.5%) patients during the premedication period.

This distribution of all adverse events occurring in ≥1% of patients over the entire monitoring period are presented in Table 6. For the entire monitoring period (premedication, anesthesia and recovery), adverse events were reported by 82/397 (21%) patients who received Midazolam overall. The most frequently reported adverse events were emesis occurring in 31/397 (8%) patients and nausea occurring in 14/397 (4%) patients. Most of these gastrointestinal events occurred after the administration of other anesthetic agents.

For the respiratory system overall, adverse events (hypoxia, laryngospasm, rhonchi, coughing, respiratory depression, airway obstruction, upper-airway congestion, shallow respirations), occurred during the entire monitoring period in 31/397 (8%) patients and increased in frequency as dosage was increased: 7/132 (5%) patients in the 0.25 mg/kg dose group, 9/132 (7%) patients in the 0.5 mg/kg dose group, and 15/133 (11%) patients in the 1 mg/kg dose group.

Most of the respiratory adverse events occurred during induction, general anesthesia or recovery. One patient (0.25%) experienced a respiratory system adverse event (laryngospasm) during the premedication period. This adverse event occurred precisely at the time of induction. Although many of the respiratory complications occurred in settings of upper airway procedures or concurrently administered opioids, a number of these events occurred outside of these settings as well. In this study, administration of Midazolam HCl syrup was generally accompanied by a slight decrease in both systolic and diastolic blood pressures, as well as a slight increase in heart rate.

Table 5. Adverse Events Occurring During the Premedication Period Before Mask Induction in the Randomized, Double-Blind, Parallel-Group Trial
Body System
No. Patients with Adverse Events
Treatment Regimen Overall
0.25 mg/kg
(n=132)
No. (%)
0.5 mg/kg
(n=132)
No. (%)
1 mg/kg
(n=133)
No. (%)
(n=397)

No. (%)
*
This adverse event occurred precisely at the time of induction.
Gastrointestinal Sytem Disorders
  Emesis 1 (0.76%) 1 (0.76%) 1 (0.75%) 3 (0.76%)
  Nausea 2 (1.5%) 2 (0.50%)
Respiratory System Disorders
  Laryngospasm 1*(0.75%) 1 (0.25%)
  Sneezing/Rhinorrhea 1 (0.75%) 1 (0.25%)
ALL BODY SYSTEMS 1 (0.76%) 1 (0.76%) 5 (3.8%) 7 (1.8%)
Table 6. Adverse Events (≥1%) From the Randomized, Double-Blind, Parallel-Group Trial on Entire Monitoring Period (premedication, anesthesia, recovery)
Body System Treatment Regimen Overall
No. Patients with Adverse Events 0.25 mg/kg
(n=132)
0.5 mg/kg
(n=132)
1 mg/kg
(n=133)
(n=397)
No. (%) No. (%) No. (%) No. (%)
Gastrointestinal System Disorders
  Emesis 11 (8%) 5 (4%) 15 (11%) 31 (8%)
  Nausea 6 (5%) 2 (2%) 6 (5%) 14 (4%)
Overall 16 (12%) 8 (6%) 16 (12%) 40 (10%)
Respiratory System Disorders
  Hypoxia 0 5 (4%) 4 (3%) 9 (2%

Recent Drug Updates at DrugIndexOnline:





Advera Advera
Some commonly used brand names are: In the U.S.— Accupep HPF 9 Advera 2 Alitraq 9 Amin-Aid 2 Attain 10 Carnation Instant Breakfast 7 Carnation Instant Breakfast No Sugar Added 7 Casec 8 CitriSource 10 Compleat Modified 1 Compleat Regular 1 Comply 10 Criticare HN 9 Crucial 2 Deliver 2.0 10 more...

Daraprim Daraprim
Generic Name: Pyrimethamine (peer-i-METH-a-meen) Brand Name: DaraprimDaraprim is used for:Treating or preventing malaria and treating toxoplasmosis when used with other medicines (eg, folinic acid). Daraprim is an antiparasitic. It works by killing the parasites or preventing their growth. Do more...

Homatropine Homatropine
Some commonly used brand names are: In the U.S.— Anaspaz 8 A-Spas S/L 8 Banthine 10 Bentyl 5 Cantil 9 Cystospaz 8 Cystospaz-M 8 Donnamar 8 ED-SPAZ 8 Gastrosed 8 Homapin 7 Levbid 8 Levsin 8 Levsinex Timecaps 8 Levsin/SL 8 Pro-Banthine 13 Quarzan 4 Robinul 6 Robinul Forte 6 Symax SL 8 Trans more...

Menomune Menomune
Generic Name: Meningococcal Vaccine (A, C, Y, W-135) (ma-nin-ja-KOK-al) Brand Name: MenomuneMenomune is used for:Preventing infection caused by certain types of meningococcal bacteria (eg, meningococcal meningitis). Menomune is a vaccine. It works by causing your immune system to produce antib more...

Miconazole Powder Miconazole Powder
Generic Name: Miconazole Powder (mi-KON-a-zole) Brand Name: Examples include Lotrimin AF and Zeasorb-AFMiconazole Powder is used for:Treating athlete's foot, jock itch, or ringworm and relieving the itching, scaling, burning, and discomfort due to those conditions. It may also be used for other more...

Norethin 1/50M Norethin 1/50M
Some commonly used brand names are: In the U.S.— Alesse 3 Brevicon 5 Cyclessa 1 Demulen 1/35 2 Demulen 1/50 2 Desogen 1 Estrostep 4 Estrostep Fe 4 Genora 0.5/35 5 Genora 1/35 5 Genora 1/50 6 Intercon 0.5/35 5 Intercon 1/35 5 Intercon 1/50 6 Jenest 5 Levlen 3 Levlite 3 Levora 0.15/30 3 Loe more...

Num-Zit Lotion Dental Num-Zit Lotion Dental
Some commonly used brand names are: In the U.S.— Anbesol, Baby 1 Anbesol Maximum Strength Gel 1 Anbesol Maximum Strength Liquid 1 Anbesol Regular Strength Gel 3 Anbesol Regular Strength Liquid 3 Benzodent 1 Chloraseptic Lozenges 2 Chloraseptic Lozenges, Children's 1 Dentapaine 1 Dent-Zel- more...

Orinase Orinase
Generic name: Tolbutamide Brand names: Orinase Why is Orinase prescribed? Orinase is an oral antidiabetic medication used to treat type 2 (non-insulin-dependent) diabetes. Diabetes occurs when the body does not make enough insulin, or when the insulin that is produced no longer works properly. I more...